Biological Role of Replication Factor C Subunit 4 in Cervical Cancer Cell Progression.

IF 1.7 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-09-01 DOI:10.21873/anticanres.17723

Seon-Joo Park, Jae Woong Koh, Tae-Bum Lee, Song Iy Han

{"title":"Biological Role of Replication Factor C Subunit 4 in Cervical Cancer Cell Progression.","authors":"Seon-Joo Park, Jae Woong Koh, Tae-Bum Lee, Song Iy Han","doi":"10.21873/anticanres.17723","DOIUrl":null,"url":null,"abstract":"Background/aim: Cervical cancer, which arises in the cervical epithelial cells, is mainly caused by persistent infection with high-risk human papillomavirus. Replication factor C subunit 4 (RFC4) is instrumental in DNA replication and repair. This study elucidated the role of RFC4 in cervical cancer by in vitro validation.Materials and methods: Quantitative real-time PCR and western blotting were performed to confirm RFC4 mRNA and protein expression levels. Following RFC4 knockdown using small interfering RNA, cervical cancer cells HeLa, ME-180, and SiHa were assessed for cell proliferation, metastatic potential, and cell cycle distribution using MTT, colony formation, migration and invasion assays, and flow cytometry.Results: RFC4 mRNA and protein expression was up-regulated in cervical cancer cells. RFC4 knockdown prevented cell proliferation, migration, and invasion in cervical cancer cells. Additionally, RFC4 knockdown induced cell-cycle arrest, inhibiting cell proliferation.Conclusion: RFC4 plays a key role in the progression and metastasis of cervical cancer cells and RFC4 may be an important therapeutic target in patients with cervical cancer.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3701-3710"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17723","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Cervical cancer, which arises in the cervical epithelial cells, is mainly caused by persistent infection with high-risk human papillomavirus. Replication factor C subunit 4 (RFC4) is instrumental in DNA replication and repair. This study elucidated the role of RFC4 in cervical cancer by in vitro validation.

Materials and methods: Quantitative real-time PCR and western blotting were performed to confirm RFC4 mRNA and protein expression levels. Following RFC4 knockdown using small interfering RNA, cervical cancer cells HeLa, ME-180, and SiHa were assessed for cell proliferation, metastatic potential, and cell cycle distribution using MTT, colony formation, migration and invasion assays, and flow cytometry.

Results: RFC4 mRNA and protein expression was up-regulated in cervical cancer cells. RFC4 knockdown prevented cell proliferation, migration, and invasion in cervical cancer cells. Additionally, RFC4 knockdown induced cell-cycle arrest, inhibiting cell proliferation.

Conclusion: RFC4 plays a key role in the progression and metastasis of cervical cancer cells and RFC4 may be an important therapeutic target in patients with cervical cancer.

查看原文本刊更多论文

复制因子C亚基4在宫颈癌细胞进展中的生物学作用

背景/目的：宫颈癌发生于宫颈上皮细胞，主要由高危人乳头瘤病毒持续感染引起。复制因子C亚基4 （RFC4）在DNA复制和修复中起重要作用。本研究通过体外验证阐明了RFC4在宫颈癌中的作用。材料和方法：采用实时荧光定量PCR和western blotting检测RFC4 mRNA和蛋白的表达水平。使用小干扰RNA敲除RFC4后，使用MTT、集落形成、迁移和侵袭试验以及流式细胞术评估宫颈癌细胞HeLa、ME-180和SiHa的细胞增殖、转移潜力和细胞周期分布。结果：RFC4 mRNA和蛋白在宫颈癌细胞中表达上调。RFC4敲低可抑制宫颈癌细胞的增殖、迁移和侵袭。此外，RFC4敲低诱导细胞周期阻滞，抑制细胞增殖。结论：RFC4在宫颈癌细胞的进展和转移中起关键作用，RFC4可能是宫颈癌患者重要的治疗靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.